| pubmed-article:1286046 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0927232 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0278721 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0657272 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:1286046 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:1286046 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1286046 | pubmed:dateCreated | 1993-3-15 | lld:pubmed |
| pubmed-article:1286046 | pubmed:abstractText | Twelve adult patients with non-leukaemic lymphoblastic lymphoma were treated with combination chemotherapy and central nervous system prophylaxis according to the protocol developed at Stanford University. Despite strict adherence to the Stanford protocol, 4 of 12 patients relapsed in the CNS, all with meningeal disease. Only four of the 12 patients are in continuing complete remission 6 to 88 months from the completion of induction therapy. These results are inferior to those previously reported for this regimen, and fail to confirm the high rate of control of CNS disease. | lld:pubmed |
| pubmed-article:1286046 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1286046 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1286046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1286046 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1286046 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1286046 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:1286046 | pubmed:author | pubmed-author:WhitehouseJ... | lld:pubmed |
| pubmed-article:1286046 | pubmed:author | pubmed-author:MeadG MGM | lld:pubmed |
| pubmed-article:1286046 | pubmed:author | pubmed-author:SweetenhamJ... | lld:pubmed |
| pubmed-article:1286046 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1286046 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:1286046 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1286046 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1286046 | pubmed:pagination | 839-41 | lld:pubmed |
| pubmed-article:1286046 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:meshHeading | pubmed-meshheading:1286046-... | lld:pubmed |
| pubmed-article:1286046 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1286046 | pubmed:articleTitle | Adult lymphoblastic lymphoma: high incidence of central nervous system relapse in patients treated with the Stanford University protocol. | lld:pubmed |
| pubmed-article:1286046 | pubmed:affiliation | CRC Wessex Medical Oncology Unit, University of Southampton, Southampton General Hospital, United Kingdom. | lld:pubmed |
| pubmed-article:1286046 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1286046 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1286046 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
